INTELLIA THERAPEUTICS INC (NTLA) Stock Fundamental Analysis

NASDAQ:NTLA • US45826J1051

13.78 USD
-0.5 (-3.5%)
At close: Feb 27, 2026
13.769 USD
-0.01 (-0.08%)
After Hours: 2/27/2026, 8:23:20 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, NTLA scores 3 out of 10 in our fundamental rating. NTLA was compared to 521 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for NTLA as it has an excellent financial health rating, but there are worries on the profitability. NTLA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • NTLA had negative earnings in the past year.
  • NTLA had a negative operating cash flow in the past year.
  • NTLA had negative earnings in each of the past 5 years.
  • In the past 5 years NTLA always reported negative operating cash flow.
NTLA Yearly Net Income VS EBIT VS OCF VS FCFNTLA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M -400M -500M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -48.18%, NTLA is in line with its industry, outperforming 51.92% of the companies in the same industry.
  • The Return On Equity of NTLA (-59.57%) is better than 60.54% of its industry peers.
Industry RankSector Rank
ROA -48.18%
ROE -59.57%
ROIC N/A
ROA(3y)-37.25%
ROA(5y)-30.46%
ROE(3y)-47.91%
ROE(5y)-38.99%
ROIC(3y)N/A
ROIC(5y)N/A
NTLA Yearly ROA, ROE, ROICNTLA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

  • NTLA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NTLA Yearly Profit, Operating, Gross MarginsNTLA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • NTLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for NTLA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NTLA Yearly Shares OutstandingNTLA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
NTLA Yearly Total Debt VS Total AssetsNTLA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • Based on the Altman-Z score of 0.63, we must say that NTLA is in the distress zone and has some risk of bankruptcy.
  • NTLA's Altman-Z score of 0.63 is fine compared to the rest of the industry. NTLA outperforms 62.26% of its industry peers.
  • NTLA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.63
ROIC/WACCN/A
WACC8.61%
NTLA Yearly LT Debt VS Equity VS FCFNTLA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

  • NTLA has a Current Ratio of 6.21. This indicates that NTLA is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 6.21, NTLA is doing good in the industry, outperforming 63.60% of the companies in the same industry.
  • A Quick Ratio of 6.21 indicates that NTLA has no problem at all paying its short term obligations.
  • The Quick ratio of NTLA (6.21) is better than 64.56% of its industry peers.
Industry RankSector Rank
Current Ratio 6.21
Quick Ratio 6.21
NTLA Yearly Current Assets VS Current LiabilitesNTLA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 27.05% over the past year.
EPS 1Y (TTM)27.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%78.81%

3.2 Future

  • NTLA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.02% yearly.
  • NTLA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 109.84% yearly.
EPS Next Y2.87%
EPS Next 2Y9.63%
EPS Next 3Y22.24%
EPS Next 5Y36.02%
Revenue Next Year-7.09%
Revenue Next 2Y20.92%
Revenue Next 3Y126.18%
Revenue Next 5Y109.84%

3.3 Evolution

NTLA Yearly Revenue VS EstimatesNTLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
NTLA Yearly EPS VS EstimatesNTLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10 -10

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NTLA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NTLA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NTLA Price Earnings VS Forward Price EarningsNTLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NTLA Per share dataNTLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as NTLA's earnings are expected to grow with 22.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.63%
EPS Next 3Y22.24%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • NTLA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INTELLIA THERAPEUTICS INC

NASDAQ:NTLA (2/27/2026, 8:23:20 PM)

After market: 13.769 -0.01 (-0.08%)

13.78

-0.5 (-3.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners87.01%
Inst Owner Change2.54%
Ins Owners1.3%
Ins Owner Change0.2%
Market Cap1.60B
Revenue(TTM)N/A
Net Income(TTM)-445.81M
Analysts72
Price Target23.94 (73.73%)
Short Float %41.04%
Short Ratio9.26
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.79%
Min EPS beat(2)5.61%
Max EPS beat(2)9.97%
EPS beat(4)4
Avg EPS beat(4)9.46%
Min EPS beat(4)5.61%
Max EPS beat(4)15.91%
EPS beat(8)7
Avg EPS beat(8)5.45%
EPS beat(12)10
Avg EPS beat(12)5.75%
EPS beat(16)11
Avg EPS beat(16)-1.99%
Revenue beat(2)1
Avg Revenue beat(2)1.92%
Min Revenue beat(2)-11.02%
Max Revenue beat(2)14.86%
Revenue beat(4)3
Avg Revenue beat(4)22.26%
Min Revenue beat(4)-11.02%
Max Revenue beat(4)47.93%
Revenue beat(8)5
Avg Revenue beat(8)8.79%
Revenue beat(12)8
Avg Revenue beat(12)8.08%
Revenue beat(16)12
Avg Revenue beat(16)14.96%
PT rev (1m)35.1%
PT rev (3m)6.37%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.41%
EPS NY rev (1m)-0.64%
EPS NY rev (3m)3.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.03%
Revenue NY rev (1m)-0.25%
Revenue NY rev (3m)-6.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 27.75
P/FCF N/A
P/OCF N/A
P/B 2.13
P/tB 2.13
EV/EBITDA N/A
EPS(TTM)-3.83
EYN/A
EPS(NY)-3.72
Fwd EYN/A
FCF(TTM)-3.56
FCFYN/A
OCF(TTM)-3.55
OCFYN/A
SpS0.5
BVpS6.46
TBVpS6.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -48.18%
ROE -59.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.25%
ROA(5y)-30.46%
ROE(3y)-47.91%
ROE(5y)-38.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.93%
Cap/Sales 3.45%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.21
Quick Ratio 6.21
Altman-Z 0.63
F-Score4
WACC8.61%
ROIC/WACCN/A
Cap/Depr(3y)130.37%
Cap/Depr(5y)126.64%
Cap/Sales(3y)24.85%
Cap/Sales(5y)23.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.65%
EPS Next Y2.87%
EPS Next 2Y9.63%
EPS Next 3Y22.24%
EPS Next 5Y36.02%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%78.81%
Revenue Next Year-7.09%
Revenue Next 2Y20.92%
Revenue Next 3Y126.18%
Revenue Next 5Y109.84%
EBIT growth 1Y47.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.5%
EBIT Next 3Y6.07%
EBIT Next 5Y8.88%
FCF growth 1Y-1.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.05%
OCF growth 3YN/A
OCF growth 5YN/A

INTELLIA THERAPEUTICS INC / NTLA FAQ

What is the ChartMill fundamental rating of INTELLIA THERAPEUTICS INC (NTLA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to NTLA.


Can you provide the valuation status for INTELLIA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to INTELLIA THERAPEUTICS INC (NTLA). This can be considered as Overvalued.


Can you provide the profitability details for INTELLIA THERAPEUTICS INC?

INTELLIA THERAPEUTICS INC (NTLA) has a profitability rating of 1 / 10.